Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant

Juan Carlos Varela, Sojung Kim, Robert D Knight, Emily Lu, Ruipeng Wang, Monzr M. Al Malki

Blood (2022) 140 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2022-170266

Published: 2022

Journal Articles

Phase 1/2 Study of Nexi-002 Autologous Multi-Antigen-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma

Robert D Knight, Myo Htut, Juan C. Varela, Andrew Kin, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik

Blood (2021) 138 (Supplement 1): 2824.

https://doi.org/10.1182/blood-2021-152185

Published: 2021

Journal Articles

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Monzr M. Al Malki, Sumithira Vasu, Dipenkumar Modi, Miguel-Angel Perales, Lucy Y Ghoda, Donna Bui, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik, Robert D Knight, Juan C. Varela

Blood (2021) 138 (Supplement 1): 4819.

https://doi.org/10.1182/blood-2021-152419

Published: 2021

Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 1942.

https://doi.org/10.1182/blood-2019-131892

Published: 2019

Journal Articles

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Irina Krapf, MSc, Yanliang Zhang, PhD, Nan Zhang, Qingdong Mark Deng, Angel Wei, MD, Robert D. Knight, MD, Jerome B. Zeldis, MD PhD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 4444.

https://doi.org/10.1182/blood-2019-131586

Published: 2019

Journal Articles

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Andrew Hau, PhD, Tong Zhu, PhD, Rengang Wang, PhD, Megan Lau, BS, Lingna Li, PhD, Xiaoqing Li, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Dalun Deng, PhD, Zheng Yan, PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD

Blood (2019) 134 (Supplement_1): 5623.

https://doi.org/10.1182/blood-2019-132080

Published: 2019

Journal Articles

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood (2017) 130 (6): 722–731.

https://doi.org/10.1182/blood-2017-04-779405

Published: 2017

Includes: Supplemental data

Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 343.

https://doi.org/10.1182/blood.V128.22.343.343

Published: 2016

Journal Articles

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Yue Gao, PhD, Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Yang, PhD, Katherine Yen, PhD, Sam Agresta, MD, Eyal C. Attar, MD, Jian Chen, PhD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Yan Li, PhD

Blood (2015) 126 (23): 2509.

https://doi.org/10.1182/blood.V126.23.2509.2509

Published: 2015

Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Blood (2015) 126 (23): 323.

https://doi.org/10.1182/blood.V126.23.323.323

Published: 2015

Journal Articles

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Rami Komrokji, MD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Rachid Baz, MD, Taiga Nishihori, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, William Dalton, PhD MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 2129.

https://doi.org/10.1182/blood.V124.21.2129.2129

Published: 2014

Journal Articles

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeffrey Lancet, Qiang Xu, PhD, Robert D. Knight, MD, Alan F. List, MD, William Dalton, PhD MD, Rami Komrokji, MD

Blood (2014) 124 (21): 1912.

https://doi.org/10.1182/blood.V124.21.1912.1912

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeff E Lancet, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, William Dalton, PhD MD, Alan F. List, MD, Rami Komrokji, MD

Blood (2014) 124 (21): 413.

https://doi.org/10.1182/blood.V124.21.413.413

Published: 2014

Journal Articles

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Blood (2010) 116 (21): 3049.

https://doi.org/10.1182/blood.V116.21.3049.3049

Published: 2010

Journal Articles

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Michael Wang, Meletios A. Dimopoulos, Christine Chen, M. Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Donna M. Weber

Blood (2008) 112 (12): 4445–4451.

https://doi.org/10.1182/blood-2008-02-141614

Published: 2008

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Antonio Palumbo, MD, Patrizia Falco, MD, Francesca Gay, MD, Paolo Corradini, MD, Claudia Crippa, MD, Francesco Di Raimondo, MD, Antonietta Falcone, MD, Nicola Giuliani, MD, Pellegrino Musto, MD, Fortunato Morabito, MD, Letizia Canepa, MD, Alessandro Gozzetti, MD, Simona Caltagirone, PhD, Jerome B. Zeldis, MD, Robert D. Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2008) 112 (11): 2768.

https://doi.org/10.1182/blood.V112.11.2768.2768

Published: 2008

Journal Articles

The Immunomodulatory Role of Lenalidomide on Prevnar ® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

Kimberly Ann Noonan, MPH, BS, Anna Ferguson, RN, Carol A. Huff, MD, Amy Emerling, Stephanie Mgebroff, Rose Wilson, Robert D. Knight, MD, Ivan M. Borrello, MD

Blood (2008) 112 (11): 2772.

https://doi.org/10.1182/blood.V112.11.2772.2772

Published: 2008

Journal Articles

Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status

Asher Chanan-Khan, MD, Meletios A Dimopoulos, MD, Donna M. Weber, Andrew Spencer, Michel Attal, MD, Andrew Belch, MD, Alessandro Corso, Tommy Fu, Jerome B. Zeldis, MD, Marta Olesnyckyj, Robert D. Knight, MD, Sagar Lonial, MD

Blood (2008) 112 (11): 3701.

https://doi.org/10.1182/blood.V112.11.3701.3701

Published: 2008

Journal Articles

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Jesús F San Miguel, Meletios A Dimopoulos, MD, Edward A. Stadtmauer, MD, S. Vincent Rajkumar, MD, David Siegel, Marie-Laure Bravo, Marta Olesnyckyj, Robert D. Knight, MD, Jerome B. Zeldis, MD, Jean-Luc Harousseau, Donna M. Weber

Blood (2008) 112 (11): 3702.

https://doi.org/10.1182/blood.V112.11.3702.3702

Published: 2008

NARROW

Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant

Phase 1/2 Study of Nexi-002 Autologous Multi-Antigen-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

The Immunomodulatory Role of Lenalidomide on Prevnar ® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only